profit from every $100 of sales.
$0$100
Champions Oncology
$4.71+1.18% today
-31.8% in 1 year
1-year low $4.651-year high $7.80
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay $13.93 for every $1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Champions Oncology sold, what it kept, and what it did with the cash.
Sales went from $49.1 million in 2022 to $56.9 million in 2025, with $4.70 million of profit last year.
SalesProfit
Champions Oncology vs. similar companies
Champions Oncology grows the slowest of these 5 and is the cheapest for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Champions Oncology | 13.9× · Cheap | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Champions Oncology's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 49 | 54 | 50 | 57 | |
| 25 | 24 | 21 | 29 | |
| 1 | -4 | -7 | 5 | |
| 2 | -2 | -5 | 6 | |
| 1 | -5 | -7 | 5 | |
| 0.04 | -0.39 | -0.54 | 0.33 | |
| 51.9% | 45.2% | 41.4% | 50.1% | |
| 1.2% | -8.3% | -13.8% | 8.5% | |
| 1.1% | -9.9% | -14.5% | 8.3% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 35 | 34 | 26 | 32 |
| Cash | 9 | 10 | 3 | 10 |
| Total debt | 9 | 9 | 7 | 6 |
| Total liabilities | 26 | 30 | 28 | 29 |
| 9 | 5 | -2 | 4 | |
| 14 | 14 | 14 | 14 | |
| 2.6% | -26.6% | -98.9% | 38.8% | |
| 6.0% | -115.1% | 382.3% | 124.6% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 6 | 4 | -6 | 7 | |
| 2 | 3 | 1 | 0 | |
| 4 | 1 | -7 | 7 | |
| Dividends paid | – | – | – | – |
| 0 | 0 | 1 | 0 | |
| 1 | 1 | 1 | 1 |
Valuation
- 13.9×
- 47.1×
- 0.14
- 19.5×
- 1.2×
- 9.4×
- 9.5×
- 10.7%
- 7.2%
- 0.0%
Profitability
- 50.1%
- 8.5%
- 8.3%
- -1.5%
- -23.2%
- -23.9%
- -57.2%
- -7.9%
- -28.6%
- 15.4%
Growth
- +5.1%
- +102.1%
- +200.3%
- –
- +1.0%
Financial health
- 2.4×
- 1.17
- 17.6%
- –
- 0.98
- 0.98
- 2.04
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 17%of 952
Bottom 47%of 884
Top 20%of 601
Bottom 31%of 886
Top 7%of 987
What analysts expect
- Average price target
- $12.00
- Range
- $12.00 – $12.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Mar 12, 2026 | -0.02 | 0.09 | −122.2% |
| Dec 15, 2025 | 0.02 | 0.08 | −75.0% |
| Sep 15, 2025 | -0.03 | 0.01 | −400.0% |
| Jul 23, 2025 | -0.13 | 0.06 | −316.7% |
| Mar 11, 2025 | 0.31 | -0.01 | +3,200.0% |
| Dec 11, 2024 | 0.05 | 0.01 | +400.0% |
| Sep 11, 2024 | 0.11 | 0.02 | +466.7% |
| Jul 18, 2024 | -0.01 | -0.16 | +93.8% |
News
Champions Oncology signals fiscal 2027 momentum as Q1 revenue reaches $15.2M and gross margin improves to 50%Seeking Alpha · Sep 10, 2026Boomers Discovered the Dividend Champions and Are Buying 5 Highest-Yielding Stocks Hand Over FistYahoo Finance · Sep 4, 2026The newest story we have is from Sep 10, 2026.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
2/7Passes 2 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
50No pass
Benjamin Graham
35No pass
Philip Fisher
62Pass
Peter Lynch
79Pass
Joel Greenblatt
37No pass
Charlie Munger
43No pass
Terry Smith
48No pass
Questions about Champions Oncology
Is Champions Oncology a good stock to buy?
A solid business, and the price looks low. 2 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Champions Oncology AI analysis
What does Champions Oncology do?
Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. It is in Biotechnology.
Does Champions Oncology pay a dividend?
No. Champions Oncology does not pay a dividend at the moment.
Is Champions Oncology stock halal?
Yes. Champions Oncology passes our halal screen: its business is permitted and its debt is 9% of its market value, under the 30% limit. How we check
How has Champions Oncology stock done over the past year?
Down 31.8% over the past twelve months, to $4.71. It traded between $4.65 and $7.80 and is 39.7% below its high.
Who are Champions Oncology's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Champions Oncology's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.